1
|
Youlden DR, Cramb SM, Dunn NA, Muller JM,
Pyke CM and Baade PD: The descriptive epidemiology of female breast
cancer: An international comparison of screening, incidence,
survival and mortality. Cancer Epidemiol. 36:237–248. 2012.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Ward C, Langdon SP, Mullen P, Harris AL,
Harrison DJ, Supuran CT and Kunkler IH: New strategies for
targeting the hypoxic tumour microenvironment in breast cancer.
Cancer Treat Rev. 39:171–179. 2013. View Article : Google Scholar : PubMed/NCBI
|
3
|
Lee JW, Bae SH, Jeong JW, Kim SH and Kim
KW: Hypoxia-inducible factor (HIF-1) α: Its protein stability and
biological functions. Exp Mol Med. 36:1–12. 2004. View Article : Google Scholar : PubMed/NCBI
|
4
|
Ohta M, Seto M, Ijichi H, Miyabayashi K,
Kudo Y, Mohri D, Asaoka Y, Tada M, Tanaka Y, Ikenoue T, et al:
Decreased expression of the RAS-GTPase activating protein RASAL1 is
associated with colorectal tumor progression. Gastroenterology.
136:206–216. 2009. View Article : Google Scholar : PubMed/NCBI
|
5
|
Ngeow J and Eng C: RASAL1 in thyroid
cancer: Wisdom from an old foe. J Natl Cancer Inst. 105:1597–1599.
2013. View Article : Google Scholar : PubMed/NCBI
|
6
|
Chen H, Cheng ZY, Pan Y, Wang Z, Liu Y and
Zhang JQ: RASAL1 influences the proliferation and invasion of
gastric cancer cells by regulating the RAS/ERK signaling pathway.
Hum Cell. 27:103–110. 2014. View Article : Google Scholar : PubMed/NCBI
|
7
|
Kolfschoten IG, van Leeuwen B, Berns K,
Mullenders J, Beijersbergen RL, Bernards R, Voorhoeve PM and Agami
R: A genetic screen identifies PITX1 as a suppressor of RAS
activity and tumorigenicity. Cell. 121:849–858. 2005. View Article : Google Scholar : PubMed/NCBI
|
8
|
Shah T, Krishnamachary B, Wildes F,
Mironchik Y and Bhujwalla ZM: Invasion and degradation of
extracellular matrix decreases in HIF-1α and HIF-2α-silenced
MDA-MB-231 human breast cancer cells. Cancer Res. 72:39432012.
View Article : Google Scholar
|
9
|
Luo W, Chang R, Zhong J, Pandey A and
Semenza GL: Histone demethylase JMJD2C is a coactivator for
hypoxia-inducible factor 1 that is required for breast cancer
progression. Proc Natl Acad Sci USA. 109:E3367–E3376. 2012.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Jing Y, Liu LZ, Jiang Y, Zhu Y, Guo NL,
Barnett J, Rojanasakul Y, Agani F and Jiang BH: Cadmium increases
HIF-1 and VEGF expression through ROS, ERK, and AKT signaling
pathways and induces malignant transformation of human bronchial
epithelial cells. Toxicol Sci. 125:10–19. 2012. View Article : Google Scholar : PubMed/NCBI
|
11
|
Wu B, Zhang F, Yu M, Zhao P, Ji W, Zhang
H, Han J and Niu R: Up-regulation of Anxa2 gene promotes
proliferation and invasion of breast cancer MCF-7 cells. Cell
Prolif. 45:189–198. 2012. View Article : Google Scholar : PubMed/NCBI
|
12
|
Kitajima Y and Miyazaki K: The critical
impact of HIF-1a on gastric cancer biology. Cancers (Basel).
5:15–26. 2013. View Article : Google Scholar : PubMed/NCBI
|
13
|
Onnis B, Rapisarda A and Melillo G:
Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med.
13:2780–2786. 2009. View Article : Google Scholar : PubMed/NCBI
|
14
|
Milosevic M, Warde P, Ménard C, Chung P,
Toi A, Ishkanian A, McLean M, Pintilie M, Sykes J, Gospodarowicz M,
et al: Tumor hypoxia predicts biochemical failure following
radiotherapy for clinically localized prostate cancer. Clin Cancer
Res. 18:2108–2114. 2012. View Article : Google Scholar : PubMed/NCBI
|
15
|
Leong HS and Chambers AF: Hypoxia promotes
tumor cell motility via RhoA and ROCK1 signaling pathways. Proc
Natl Acad Sci USA. 111:887–888. 2014. View Article : Google Scholar : PubMed/NCBI
|
16
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
|
17
|
Meijer TW, Kaanders JH, Span PN and
Bussink J: Targeting hypoxia, HIF-1, and tumor glucose metabolism
to improve radiotherapy efficacy. Clin Cancer Res. 18:5585–5594.
2012. View Article : Google Scholar : PubMed/NCBI
|
18
|
Liu D, Yang C, Bojdani E, Murugan AK and
Xing M: Identification of RASAL1 as a major tumor suppressor gene
in thyroid cancer. J Natl Cancer Inst. 105:1617–1627. 2013.
View Article : Google Scholar : PubMed/NCBI
|